Clinical trial · Interventional

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

NCT07107178CI-TRIAL-00093160not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Advanced Melanoma	Melanoma	CURATED_BROADER	0.78
Advanced Solid Tumor	Solid Neoplasm	CURATED_BROADER	0.80

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
BT02	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
dose escalation and expansion
interventionNames
1. Drug: BT02

Primary outcomes (4)

measure
Adverse events
timeFrame
Through the study completion, an average of 2 years
measure
Dose limited toxicity(DLT)
timeFrame
Through the dose escalation phase, an average of 8 months
measure
Maximum tolerable dose(MTD)
timeFrame
Through the dose escalation phase, an average of 8 months
measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 75 Years

Show eligibility criteria text

Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy .
2. Adequate organ and hematologic function.
3. At least 1 extracranial measurable lesion.
4. An ECOG activity status score of 0-1.
5. A life expectancy of ≥ 3 months.
6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period.
7. Good compliance and willingness to follow up.

Exclusion Criteria:

1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days.
2. A history of active autoimmune disease within the past 2 years.
3. A history of clinically significant cardiovascular disease, severe cardiac rhythm/conduction abnormalities or LVEF\<50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea.
4. A severe acute or chronic infection when enrollment.
5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .
6. Unresolved \> grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product.
7. Clinically active CNS metastases or meningeal metastases.
8. A history of other type of malignancies.
9. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product.
10. Poor compliance.
11. A history of alcohol/drugs abuse.
12. Current pregnancy or breastfeeding.
13. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.

References

Publications (0)

Data not yet available

No reference posted for this study.